-
Formosa Pharmaceuticals Strikes Licensing Deal with Cristália for Ocular Surgery Pain Treatment in Brazil
•
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based Cristália Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Cristália the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential…
-
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
•
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans to shut down two of its factories, one in the US and another in China. The report states that this decision is made “in the context of current market dynamics” and is part of efforts…
-
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
•
A bipartisan bill introduced on January 26, 2024, by members of the US House Select Committee on strategic competition between the US and China has caused a significant decline in the share prices of various China-based biotech and contract development organizations (CDOs) last week. The companies have begun to respond…
-
Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China
•
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its drug Leqembi (lecanemab), an amyloid-beta (Aβ)-targeting therapy indicated for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). This…
-
Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center
•
The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology industrial park, marking a significant step forward for the region’s bio-industry. Within this park, Hunan Norchem Pharmaceutical Co., Ltd is preparing to establish the inaugural synthetic biology research and development center in East China, reinforcing…
-
Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories
•
Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to form a joint venture (JV) with MegaRobo Technologies, a Beijing-based firm renowned for its integration of robotics and artificial intelligence (AI) in life sciences. This strategic partnership aims to pioneer industry-standard medical laboratory automation solutions,…
-
Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the first international shipment of its anti-programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab), from Shanghai Pudong Airport to Indonesia. HanSiZhuang, the inaugural innovative monoclonal antibody (mAb) developed by Henlius, has gained approval from the National Medical Products…
-
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for its pipeline drug candidate, FCN-338. This small-molecule Bcl-2 inhibitor will…
